Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Sarcoma 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 7Cyclophosphamide 7Surveys and Questionnaires 4Filgrastim 4aldesleukin 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Nivolumab 3Methods 3Flow Cytometry 3Early Intervention, Educational 3valspodar 2sargramostim 2fludarabine 2atezolizumab 2Therapeutics 2Stem Cell Factor 2Sirolimus 2Methylprednisolone 2Melphalan 2Ipilimumab 2Interleukin-2 2Immunologic Techniques 2Exercise 2Etoposide 2Epoetin Alfa 2Educational Status 2Drug Therapy 2Data Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × LY3023414 × Breast × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡